Goldman Sachs raised the firm’s price target on Moderna (MRNA) to $49 from $43 and keeps a Neutral rating on the shares after it’s Q1 results. The company’s oncology pipeline assets remain in focus as Moderna’s next leg of growth, including a Phase 3 Merck-partnered individualized neoantigen vaccine intismeran and Phase 2 data likely out this year or early 2027 in adjuvant renal cell carcinoma, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna price target raised to $33 from $30 at Morgan Stanley
- Midday Fly By: Apple reports Q2 beat, oil majors post mixed results
- Moderna price target raised to $32 from $31 at BofA
- Moderna: Solid Q1 Beat and EU Combo Vaccine Approval Offset by Regulatory Setbacks and Long Path to 2028 Breakeven, Justifying Hold Rating
- Morning Movers: Roblox and Western Digital sink after earnings